This article is provided for educational and informational purposes only. All compounds discussed are analytical-grade biochemical reference standards supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption, therapeutic use, or administration of any kind.
A Certificate of Analysis is where a research-grade compound either earns your trust or loses it. For a compound like tesamorelin. a 44-amino-acid GHRH analog that’s been studied for more than two decades in the growth hormone secretagogue literature. the paperwork matters as much as the powder in the vial.
Ferdinandi and colleagues published the foundational pharmacokinetic and structural characterization work on tesamorelin back in 2007 in Basic & Clinical Pharmacology & Toxicology (PMID: 17593254), establishing the analytical baseline that every downstream reference standard is measured against. The compound has a defined molecular weight (5,196 Da), a specific amino acid sequence, and a well-characterized degradation profile. Any laboratory working with it deserves documentation that reflects that specificity.
This guide walks through what a rigorous tesamorelin reference standard COA actually contains. identity by LC-MS, purity by HPLC-UV, net compound content, counter-ion composition, residual solvent screening. and what each number tells a research customer about the material in front of them. It’s written for qualified research customers evaluating analytical-grade biochemical reference standards for in-vitro research, analytical method development, and identity verification. For laboratory research use only.
Tesamorelin is a synthetic 44-amino-acid compound analog of human GHRH (1–44). Structurally, it’s built on the native GHRH backbone with a trans-3-hexenoic acid group attached at the N-terminus. That modification. a fatty acid tail on tyrosine. is the entire reason the molecule exists as a separate compound. Native GHRH gets chewed up by dipeptidyl peptidase-4 within minutes.
The hexenoic acid modification blocks that cleavage site, and the half-life climbs from something like two minutes to something more useful for research protocols.
The full amino acid sequence, verified in Ferdinandi’s 2007 characterization work (PMID: 17593254), is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2. The C-terminal is amidated. The N-terminal carries the trans-3-hexenoyl modification. Molecular formula: C221H366N72O67S. Molecular weight: 5,196 Da (5,195.79 to be exact, but rounding to 5,196 is standard practice on reference-standard documentation).
All of that is what a reference standard for tesamorelin needs to prove it actually is. The COA is where the proof lives.
In preclinical and analytical-method-development work, tesamorelin serves several purposes. Analytical chemists use it as an identity standard for LC-MS method development targeting GHRH-family compounds. Researchers studying growth hormone secretagogue pathway biology use it as an in-vitro binding reference. Falutz and colleagues (2010, Journal of Clinical Endocrinology & Metabolism, PMID: 20554713) established the receptor-level pharmacology that downstream cellular assays are calibrated against.
It also appears in pharmaceutical impurity-profiling workflows where a well-characterized lot is used to identify degradation products in unknown samples.
None of those research uses requires the material to be sterile, endotoxin-free, or otherwise prepared for clinical work. What they do require is analytical certainty about what’s in the vial. That’s what the COA delivers.
The research-grade compound category has a documentation problem. Some vendors ship product with no COA at all. Others ship the same static PDF with every shipment. a document produced once, years ago, on a batch that has nothing to do with what’s actually in the shipment. Others produce COAs internally, with no independent lab involved, which turns the document into a marketing artifact rather than an analytical one.
A real reference-standard COA has three properties: it’s batch-specific (tied to a specific lot number that matches the vial label), it’s independently produced (issued by an analytical laboratory separate from the seller), and it’s method-transparent (each reported parameter names the analytical technique used to produce it).
The Vitro Labs COA for tesamorelin is issued by Freedom Diagnostics, an ISO-certified independent analytical laboratory in Franklin, Tennessee. Every batch of tesamorelin 5mg gets its own document. The batch number on the vial matches the batch number on the COA. If you requisition two vials from different lots, you get two separate COAs. because they’re two separate batches of material.
Identity is the first thing a COA needs to establish. Before you look at purity, before you look at counter-ions, before you look at anything else, you need to know whether the vial contains the molecule the label says it contains. The technique that answers that question is LC-MS (liquid chromatography–mass spectrometry).
The workflow is straightforward. A small quantity of the sample is dissolved and injected into a liquid chromatography system, which separates it from any co-eluting components. The separated compound then enters a mass spectrometer, which ionizes the molecule and measures its mass-to-charge ratio with high precision. For a compound the size of tesamorelin, the expected result is a set of multiply-charged ions. typically the [M+4H]⁴⁺, [M+5H]⁵⁺, and [M+6H]⁶⁺ species. from which the deconvoluted monoisotopic mass can be calculated.
For tesamorelin, that deconvoluted mass should land at 5,195.79 Da (monoisotopic) or 5,199.10 Da (average). A COA reporting an observed mass of 5,196.1 Da against an expected mass of 5,196.0 Da is consistent with the correct molecule. A COA reporting an observed mass 20 Da off, or a COA that doesn’t report a numerical mass at all, isn’t doing its job.
LC-MS identity confirmation tells you that the primary component in the sample has the correct mass. It doesn’t, by itself, tell you what fraction of the sample that primary component represents. A material can have correct identity and terrible purity at the same time. that’s what makes the next parameter, HPLC purity, essential.
Purity is measured by HPLC-UV. The sample is pushed through a chromatography column under high pressure; different components exit the column at different times based on their chemical properties. A UV detector measures how much material is exiting at each moment. The resulting chromatogram is a series of peaks. a big one for the target molecule, small ones for impurities and degradation products.
Purity is calculated as the area of the target peak divided by the total area of all peaks, expressed as a percentage.
| HPLC purity range | What it indicates | Typical research use |
|---|---|---|
| ≥99% | Analytical-grade reference material | Method development, quantitative standards |
| 98.0–98.9% | Analytical-grade threshold | Preclinical research, identity standards |
| 95–97.9% | Research-grade, some impurities present | Exploratory in-vitro work |
| Below 95% | Crude or partially purified material | Not suitable as a reference standard |
For tesamorelin, the analytical-grade threshold is ≥98.0% by HPLC. Vitro’s tesamorelin batches are specified at ≥98%, with actual measured values typically higher.
The 2% or less that isn’t tesamorelin in a high-purity batch isn’t random contamination. It’s typically a small population of structurally related species. deletion sequences (where a residue was skipped during synthesis), truncation products (where synthesis stopped short), deamidation products (where an asparagine or glutamine residue has hydrolyzed), and oxidation products (where a methionine or cysteine has picked up an oxygen).
Grochow and colleagues (2009, Journal of Pharmaceutical and Biomedical Analysis, PMID: 19632072) described the characteristic impurity profile for tesamorelin from solid-phase synthesis, and the pattern is what you’d expect for a 44-mer: a low-single-digit percentage spread across a handful of related peaks.
A COA that reports 98.4% tesamorelin with the balance identified as characteristic synthesis-related impurities is telling a coherent chemistry story. A COA that reports 98% tesamorelin with no discussion of what the remaining 2% is. or worse, a COA reporting numbers so clean they look implausible. deserves scrutiny.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. Tesamorelin is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
Here’s the parameter that trips up more researchers than any other: net compound content. It’s also called compound content, compound assay, or compound by mass.
When a vial is labeled “5 mg tesamorelin,” that mass number refers to the total mass of solid in the vial. the compound plus everything else that comes packaged with it. Synthetic compounds made by solid-phase synthesis and purified as trifluoroacetate or acetate salts always ship with counter-ions and residual water attached. Those additions aren’t contamination; they’re a structural feature of how the molecule exists as a stable solid.
So a vial labeled “5 mg” might contain 3.9 mg of actual tesamorelin amino-acid backbone, 0.6 mg of acetate counter-ions, and 0.5 mg of residual water. Net compound content on the COA would report that as ~78% compound by mass.
For qualitative work. confirming a peak on a chromatogram, running a receptor-binding assay at approximate concentrations. the difference between total mass and compound mass rarely matters. For quantitative work. building a calibration curve, calculating precise binding constants, generating publication-grade quantitative data. the compound content number is the one you use to calculate actual molar concentrations. Using the labeled mass instead of the net compound content will give you results that are systematically off by 15–25%.
Rigorous methodology guidance from the compound chemistry literature (Van Regenmortel and colleagues, 2001, Journal of Molecular Recognition, PMID: 11813262) has argued for years that compound content assay should be reported on every reference standard COA. The Vitro Labs COA reports it.
The counter-ion is the negatively-charged species that pairs with the basic residues on the compound (lysines, arginines, histidines) to form a stable salt. Two counter-ions dominate synthetic compound production: trifluoroacetate (TFA) and acetate.
TFA is the byproduct of the deprotection chemistry used in solid-phase synthesis. It ships with the compound unless it’s explicitly removed. It’s inexpensive, and it’s fine for most analytical work. It’s less fine for cellular research because TFA at higher concentrations has been documented as biologically active in some assays. Cornish and colleagues (1999, Compounds, PMID: 10513598) reported cell-culture effects attributable to residual TFA that would confound sensitive in-vitro work.
Acetate is the alternative counter-ion produced by ion-exchange during a secondary purification step. It’s biologically neutral in the vast majority of cellular assay conditions and it’s the preferred counter-ion for reference standards intended for in-vitro pathway research. Tesamorelin as a research reference standard is typically supplied as the acetate salt.
A tesamorelin COA should report acetate content as a percentage of total mass, typically in the 5–12% range. It should also verify that TFA content is below a specified threshold (often <0.5% or non-detected). If the counter-ion isn’t reported, or if TFA is reported at higher percentages without acknowledgment, the material may not be suitable for sensitive cellular work.
Solid-phase synthesis uses organic solvents. most commonly DMF (N,N-dimethylformamide), acetonitrile, and DCM (dichloromethane). Residual amounts persist in the lyophilized final material unless the drying process is thorough.
A residual solvents panel on the COA reports the concentration of each of these in parts per million (ppm), typically screened by gas chromatography. The ICH Q3C guideline for pharmaceutical residual solvents (International Council for Harmonisation, 2019 revision) sets class-based limits: Class 2 solvents like acetonitrile capped at 410 ppm, DMF capped at 880 ppm, and so on.
For research-grade reference standards, residual solvents are relevant because they can interfere with cellular assays at high concentrations. A COA that reports all major synthesis solvents below their ICH limits. or reports them as “not detected”. is documenting that the material has been dried and purified thoroughly enough for downstream research use.
The most old-fashioned parameter on the COA is also one of the most useful: what does the material look like?
Lyophilized tesamorelin should appear as a white to off-white amorphous powder or cake. Yellow discoloration suggests degradation. Crystalline formations suggest the material was reconstituted and re-dried, which is a red flag for a supposedly virgin reference standard. Visible particulates suggest contamination or handling problems during vialing.
The COA appearance line should read something like “White to off-white lyophilized powder.” It’s a low-tech check, but it’s the check a researcher can actually perform themselves when the vial arrives, and it’s the fastest way to catch a lot that shouldn’t have shipped.
Being explicit about the boundary of the document matters. Vitro Labs COAs report identity, purity, net compound content, appearance, and method. They do not report:
None of those tests are required for the intended use of an analytical-grade biochemical reference standard in in-vitro research, analytical method development, or identity verification. Vendors that claim endotoxin, sterility, or heavy-metal testing without a clinical-manufacturing infrastructure behind the claim are typically overclaiming. the specifications on retail research-grade compound COAs frequently don’t match what those tests actually require in practice.
If a research application specifically requires endotoxin-tested or sterility-tested material, that work belongs at a supplier operating under GMP or equivalent quality systems, with a different price point and a different documentation framework.
Here’s how the pieces fit together in practice. A Vitro Labs tesamorelin 5mg COA. issued by Freedom Diagnostics against a specific batch number. will typically report a document structured roughly like this:
The header of the document ties it to a specific batch. The body reports specific numerical values against specification thresholds. The footer names the analyst and the analytical methods used. Every number can be traced back to a specific instrument run on a specific day.
When you receive a vial of tesamorelin from Vitro Labs, the batch number on the vial label matches the batch number on the COA in your account documentation. That match is the whole point.
Freedom Diagnostics is an ISO-certified independent analytical laboratory based in Franklin, Tennessee. They’re the lab that produces every COA that ships with a Vitro Labs shipment. They’re independent. meaning they’re not owned by or operated as part of Vitro Labs. and they operate under an ISO quality-management framework that governs how their instruments are calibrated, how their methods are validated, and how their reports are produced.
The value of independent testing isn’t magic. It’s the removal of a specific conflict of interest: the party selling the material is not the party grading the material. That separation is what turns a COA from a marketing document into an analytical one. If the seller controls the numbers on the report, the numbers on the report reflect what the seller wants them to reflect. If an independent lab controls the numbers, the numbers reflect the instruments.
ISO certification adds a second layer: the independent lab operates under a documented quality system that external auditors periodically review. It doesn’t guarantee any specific batch is any specific quality. It does guarantee that the process by which the batch was tested is a process someone external has looked at.
Not every document that calls itself a Certificate of Analysis is one. A short checklist of red flags:
A COA typically documents the state of the material at time of testing. Storage recommendations for maintaining that state through the material’s shelf life are usually printed on the label or included in accompanying documentation rather than the COA itself.
For lyophilized tesamorelin, standard storage guidance in the compound chemistry literature (Manning and colleagues, 2010, Pharmaceutical Research, PMID: 20143256) is –20°C or lower, protected from light, in a sealed vial with desiccant. Under those conditions, a well-lyophilized 44-mer like tesamorelin has documented stability profiles extending 24 months or longer without significant degradation.
Once reconstituted, stability drops dramatically. the compound is now in solution, exposed to water, and susceptible to hydrolytic and oxidative degradation pathways. Reconstituted stability is a research-protocol variable that depends on the buffer system, the storage temperature, and the intended use of the material. It’s not something the batch COA speaks to; it belongs in the research protocol documentation for the specific study using the material.
Tesamorelin’s regulatory status is worth understanding as sourcing context. It has been evaluated by the FDA under the brand name Egrifta for a specific clinical indication, and Falutz and colleagues published the pivotal clinical characterization work referenced above (PMID: 20554713). That clinical development history means the compound has been extensively characterized in the peer-reviewed literature. which is useful for research protocols because it means analytical methods, structural characterization, and pharmacokinetic parameters are all publicly available.
None of that regulatory history changes the status of tesamorelin as an analytical-grade biochemical reference standard when supplied by Vitro Labs. The material is supplied strictly for laboratory research, analytical method development, identity verification, and in-vitro evaluation by qualified research customers. It is not approved for human or animal consumption, therapeutic use, diagnostic use, or administration of any kind in the format supplied by Vitro Labs.
Every batch ships with its Freedom Diagnostics COA. Every batch is traceable back to its specific analytical documentation. Researchers evaluating the material for their laboratory work can request the COA in advance of requisitioning, review it against their specifications, and confirm the batch details before adding the material to laboratory inventory. Documentation-first sourcing is the whole discipline; the COA is where it lives.
For more on Vitro’s editorial standards and citation policies, see Editorial Standards. To review sample COAs across the catalog, see Certificates of Analysis. For related material on tesamorelin’s mechanism and pharmacology, see the Tesamorelin GHRH Analog Research Guide. To review the tesamorelin product page directly, see Tesamorelin 5mg.
“The analytical characterization of a compound reference material is not a formality. It is the foundation upon which all downstream quantitative research rests.”
, Van Regenmortel et al. (2001), PMID: 11813262
Identity is verified by LC-MS (liquid chromatography–mass spectrometry). The technique separates the sample chromatographically, then measures the mass-to-charge ratio of the ionized compound. For tesamorelin, the deconvoluted mass should match 5,196 Da (average) or 5,195.79 Da (monoisotopic), consistent with the molecular formula C221H366N72O67S first characterized by Ferdinandi et al. (2007, PMID: 17593254). A COA reporting an observed mass within a fraction of a Dalton of the expected value is documenting correct identity.
The analytical-grade threshold for tesamorelin reference standards is ≥98% by HPLC-UV. Purity is calculated as the area of the tesamorelin peak divided by the total area of all peaks on the chromatogram, expressed as a percentage. Values in the 95–97.9% range indicate research-grade material with more significant impurity profiles; values below 95% suggest crude or partially purified material not suitable as a reference standard. Vitro Labs tesamorelin batches are specified at ≥98%.
Net compound content and HPLC purity measure different things. HPLC purity measures what fraction of the compound-containing peaks belong to tesamorelin. this is where the ≥98% value comes from. Net compound content measures what fraction of the total solid mass in the vial is amino-acid backbone, with the balance being acetate counter-ions (5–15%) and residual water (3–10%). Both numbers are correct simultaneously. Researchers doing quantitative work should use net compound content to calculate actual molar concentrations rather than the labeled mass.
TFA (trifluoroacetate) is the default counter-ion from solid-phase synthesis and is fine for most analytical work. Acetate is produced by a secondary ion-exchange step and is preferred for reference standards intended for sensitive in-vitro cellular research, because TFA has documented biological activity in some cellular assay conditions (Cornish et al., 1999, PMID: 10513598) that can confound results. Tesamorelin supplied as an analytical-grade reference standard is typically the acetate salt, with the counter-ion identity and content reported on the COA.
No. Vitro Labs COAs report identity (LC-MS), purity (HPLC-UV), net compound content, appearance, and analytical methods. Endotoxin, sterility, and heavy-metal testing are not performed by Vitro Labs and are not represented on our COAs. These parameters are not required for the intended use of analytical-grade biochemical reference standards in in-vitro research, analytical method development, and identity verification. Research applications requiring endotoxin- or sterility-tested material belong at suppliers operating under GMP-equivalent quality systems.
Freedom Diagnostics is an ISO-certified independent analytical laboratory in Franklin, Tennessee. Because they are not owned by or operated as part of Vitro Labs, they have no commercial interest in the outcome of any specific analytical run. This separation removes the conflict of interest inherent in a seller producing its own test documentation. Additionally, ISO certification requires the laboratory to operate under a documented quality-management system with periodic external audit, providing external verification of the testing process itself. not just the individual results.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. Tesamorelin is a research compound not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
